Anti-TMEFF2/Anti-CD3 Bispecific Antibody JNJ-70218902

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A T-cell redirecting agent and bispecific antibody targeting both the prostate cancer lineage antigen tomoregulin-2 (transmembrane protein with EGF-like and two follistatin-like domains 2; TMEFF2; TENB2) and the T-cell surface receptor CD3, with potential immunomodulating and antineoplastic activities. Upon administration, anti-TMEFF2/anti-CD3 bispecific antibody JNJ-70218902 targets and binds to both TMEFF2 expressed on tumor cells and CD3 expressed on T-cells. The resulting cross-linkage activates and redirects T-cells to TMEFF2-expressing tumor cells. This results in T-cell-mediated lysis of tumor cells. TMEFF2, a transmembrane protein with epidermal growth factor-like and 2 follistatin-like domains, is normally expressed in healthy brain and prostate and overexpressed in prostate cancer.

**Synonyms:** - Anti-TMEFF2/CD3 Bispecific Antibody JNJ-70218902 - JNJ 70218902 - JNJ 902 - JNJ-70218902 - JNJ-902 - JNJ70218902 - JNJ902 - T-cell Redirecting Agent JNJ-70218902 - TMEFF2 x CD3 Bispecific Antibody JNJ-70218902